294 related articles for article (PubMed ID: 21764801)
1. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.
Herholz K; Westwood S; Haense C; Dunn G
J Nucl Med; 2011 Aug; 52(8):1218-26. PubMed ID: 21764801
[TBL] [Abstract][Full Text] [Related]
2. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
3. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
Llano DA; Laforet G; Devanarayan V;
Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
5. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
[TBL] [Abstract][Full Text] [Related]
6. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga A; Grimmer T; Riemenschneider M; Lautenschlager N; Siebner H; Alexopoulus P; Minoshima S; Schwaiger M; Kurz A
J Nucl Med; 2005 Oct; 46(10):1625-32. PubMed ID: 16204712
[TBL] [Abstract][Full Text] [Related]
7. MRI or
Doering E; Antonopoulos G; Hoenig M; van Eimeren T; Daamen M; Boecker H; Jessen F; Düzel E; Eickhoff S; Patil K; Drzezga A;
J Nucl Med; 2024 Jan; 65(1):147-155. PubMed ID: 38050112
[TBL] [Abstract][Full Text] [Related]
8. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
Landau SM; Harvey D; Madison CM; Koeppe RA; Reiman EM; Foster NL; Weiner MW; Jagust WJ;
Neurobiol Aging; 2011 Jul; 32(7):1207-18. PubMed ID: 19660834
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET.
Shokouhi S; Claassen D; Kang H; Ding Z; Rogers B; Mishra A; Riddle WR;
J Nucl Med; 2013 Sep; 54(9):1564-9. PubMed ID: 23864720
[TBL] [Abstract][Full Text] [Related]
10. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
[TBL] [Abstract][Full Text] [Related]
11. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.
Torosyan N; Mason K; Dahlbom M; Silverman DHS;
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1355-1363. PubMed ID: 28331953
[TBL] [Abstract][Full Text] [Related]
12. Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.
Bensamoun D; Guignard R; Furst AJ; Derreumaux A; Manera V; Darcourt J; Benoit M; Robert PH; David R
J Alzheimers Dis; 2016; 49(2):387-98. PubMed ID: 26484900
[TBL] [Abstract][Full Text] [Related]
13. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
[TBL] [Abstract][Full Text] [Related]
15. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
16. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
Schmand B; Eikelenboom P; van Gool WA;
J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study.
Ito K; Fukuyama H; Senda M; Ishii K; Maeda K; Yamamoto Y; Ouchi Y; Ishii K; Okumura A; Fujiwara K; Kato T; Arahata Y; Washimi Y; Mitsuyama Y; Meguro K; Ikeda M;
J Alzheimers Dis; 2015; 45(2):543-52. PubMed ID: 25589723
[TBL] [Abstract][Full Text] [Related]
18. Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease.
Dodge HH; Zhu J; Harvey D; Saito N; Silbert LC; Kaye JA; Koeppe RA; Albin RL;
Alzheimers Dement; 2014 Nov; 10(6):690-703. PubMed ID: 25022534
[TBL] [Abstract][Full Text] [Related]
19. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.
Mosconi L; De Santi S; Li Y; Li J; Zhan J; Tsui WH; Boppana M; Pupi A; de Leon MJ
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):210-21. PubMed ID: 16311757
[TBL] [Abstract][Full Text] [Related]
20. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
